CD30 Antibody (D-7): sc-514270
- CD30 Antibody (D-7) is a mouse monoclonal IgG2b κ provided at 200 µg/ml
- specific for an epitope mapping between amino acids 21-43 at the N-terminus of CD30 of human origin
- recommended for detection of CD30 long form of human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for CD30 Antibody (D-7) for WB applications. These reagents are now offered in bundles with CD30 Antibody (D-7) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD30 Antibody (D-7) is a mouse monoclonal IgG2b antibody that detects CD30 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CD30 is a member of the tumor necrosis factor receptor family and is primarily expressed on activated T and B lymphocytes, as well as neoplastic cells associated with Hodgkin′s lymphoma and other hematologic malignancies. CD30 expression on these cells serves as a marker for diagnosis and prognosis in various lymphoproliferative disorders. Upon binding with CD30L, CD30 initiates signaling pathways that can lead to cell proliferation, survival, and differentiation, making CD30 an important target for therapeutic interventions. CD30 interacts with specific proteins such as TRAF2 and TRAF5, which are essential for mediating downstream signaling cascades that influence immune responses and cell fate decisions. Anti-CD30 antibody (D-7) effectively recognizes and binds to CD30, making this antibody a valuable tool for researchers studying immune regulation and the pathogenesis of lymphoid malignancies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD30 Antibody (D-7) References:
- Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. | Oflazoglu, E., et al. 2009. Adv Exp Med Biol. 647: 174-85. PMID: 19760074
- Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies. | Fabbri, A., et al. 2017. Anticancer Agents Med Chem. 17: 886-895. PMID: 27592544
- Brentuximab vedotin for CD30-positive tumours. | Masuda, S., et al. 2016. Lancet Oncol. 17: e371. PMID: 27599139
- Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. | Wang, Y., et al. 2018. J Hematol Oncol. 11: 57. PMID: 29685160
- CD30 expression and survival in posttransplant lymphoproliferative disorders. | Kinch, A., et al. 2020. Acta Oncol. 59: 673-680. PMID: 32102582
- Persistent Agminated CD30+ Lymphoproliferative Disorder. | Beer, J., et al. 2020. J Drugs Dermatol. 19: 1005-1007. PMID: 33026773
- Advances in CD30- and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma. | Ma, H., et al. 2021. Am J Transl Res. 13: 12206-12216. PMID: 34956447
- Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders. | Abdulla, FR., et al. 2022. JID Innov. 2: 100068. PMID: 34977845
- CD30+ Transformed Mycosis Fungoides Associated with Sweet-like Dermatosis. | André, F., et al. 2022. Acta Derm Venereol. 102: PMID: 35356992
- Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. | Brudno, JN., et al. 2024. Blood Adv. 8: 802-814. PMID: 37939262
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD30 Antibody (D-7) | sc-514270 | 200 µg/ml | $322.00 | |||
CD30 Antibody (D-7): m-IgG Fc BP-HRP Bundle | sc-538613 | 200 µg Ab; 10 µg BP | $361.00 | |||
CD30 Antibody (D-7): m-IgGκ BP-HRP Bundle | sc-536257 | 200 µg Ab; 40 µg BP | $361.00 | |||
CD30 (D-7) Neutralizing Peptide | sc-514270 P | 100 µg/0.5 ml | $69.00 |